Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JADE201
- Development stage
- Phase 1
- Lead developer
- Jade Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
JADE201 is an investigational monoclonal antibody drug candidate developed by Jade Biosciences. It was nominated as a development candidate from the company’s JADE-002 antibody discovery program and is currently in preclinical development. While specific details about its molecular target, mechanism of action, or intended disease indication have not been publicly disclosed as of June 2025, it is part of Jade Biosciences’ pipeline focused on therapies for autoimmune diseases. The company’s lead asset (JADE101) targets APRIL for IgA nephropathy; however, no such mechanistic or disease-specific information has yet been released for JADE201[2][4][8][10].
Beyond the preview
Go deeper on JADE201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JADE201.